Supriya Lifescience Q4 FY26: Anesthetics Surge, Margins Hold the Line

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

The company clocked ₹277 cr in Q4 revenue, +50% YoY, after a quiet Q3. EPS for the full year stands at ₹25.98 against a stock price of ₹919, placing the market multiple at 35.3x annualised earnings.

Anesthetics revenue jumped to 49% of FY26 from 37% in FY25 — a portfolio shift, not just margin expansion.

The working capital tightened: debtor days stretched to 97 from 70 in the prior year. Backward integration now covers 76% of FY26 revenue, a structural floor.

Ambarnath facility began recognising revenue in Q4 after months of capex burn. DSM contract stabilised at ₹30–35 cr for the year, with peak expected around ₹60 cr.

The tension: can the company defend 33–35% EBITDA margins while absorbing two new manufacturing sites, elevated receivables, and a product pipeline scaling from semi-regulated into controlled markets?

2 — Introduction

Supriya Lifescience trades a niche position: 40+ APIs across antihistamines, analgesics, anesthetics, vitamins, and anti-asthmatics, with 82% of FY26 revenue flowing from exports across 120 countries and 1,500 customers.

Founded in 1987 as a chemical partnership, incorporated as a public company in 2008, listed in December 2021, the company has spent the last three years building capacity ahead of demand.

The FY26 results arrived May 27, 2026. Revenue grew 18.9% YoY to ₹828 cr; PAT rose 11.3% to ₹209 cr, carried by Q4’s 50% topline burst. EBITDA expanded 12.8% to ₹294 cr with margin contracting 192 bps to 35.5%.

Capex ran ₹152 cr in FY26, mostly directed at Ambarnath (a CMO/CDMO facility 60 km from Nhava Sheva Port, 50 km from Mumbai Airport). A second greenfield at Patalganga has secured clearances; Phase-1 capex earmarked ~₹200 cr begins FY27.

Management guided ₹1,000 cr revenue by FY27 (requiring ~21% growth) and reaffirmed a 20% revenue CAGR with 33–35% EBITDA margins.

3 — Business Model: WTF Do They Even Do?

The core: Supriya manufactures advanced pharmaceutical ingredients — bulk drugs, controlled substances, complex molecules — and sells them to global finished-dosage makers and CMO/CDMO customers.

The model rests on three pillars.

First, backward integration: 20 products tie raw materials in-house (anesthetics, anti-asthmatics, vitamins, anti-gouts). This covers 76% of FY26 revenue. The advantage is real — supply certainty, price hedging, margin compression avoidance.

Second, niche positioning: the portfolio sits at the margin of pharma — ketamine, esketamine, brompheniramine, salbutamol, various B vitamins. These aren’t commodity APIs; they serve therapies where demand is steady, global, and less price-war afflicted than generics. Regulatory hurdles (CEPs, DMFs, FDA approvals) create a moat.

Third, geography. Supriya ships 82% of production abroad. Europe sits at 40% of FY26 revenue, Asia at 33%, LatAm at 20%, North America at 3%. The distribution mix reduces concentration and hedges currency.

Q4’s revenue bump came from anesthetics — a single product line scaling from LatAm and Europe. Management signalled this is durable: cardiovascular API, liquid anesthetic, and ADHD APIs (all launched in FY25–26) are already feeding into Q4 and queuing for ramp-up through FY27.

The roast: Supriya is building finished-dosage capacity (Ambarnath, Patalganga) but won’t see material revenue contribution for “three to four years.” It’s a bet that CMO/CDMO margins are fat enough to justify the wait. Management also targets contrast media, a higher-complexity molecule, but delayed it — “margin discipline,” they said — waiting for a more efficient synthesis route. This patience is rare in Indian pharma.

4 — Financials Overview

Figures are consolidated, in ₹ crore.

Quarterly Results (Q4 FY26 vs Q4 FY25)

Q4 revenue accelerated past Q3 (₹206 cr) and Q4 FY25 (₹158 cr). EBITDA margin held at 35.3% in Q4 vs 36.7% a year prior; operating margin pressure emerged from pre-revenue spending at Ambarnath (management explicitly cited this).

Full-Year FY26 vs FY25

PAT margin compressed to 25.3% from 27.0% (173 bps headwind), reflecting Ambarnath’s operating leakage and higher raw material cost in the latter half.

Concall Colour

Management attributed FY26’s margin optics to Ambarnath pre-revenue expenses already flowing through the P&L while revenue “has still not started.” They expect this facility to contribute meaningfully in FY27–28, with “full effect” in 2–4 years.

The company guided a near-term margin band of 33–35%, not a gradual structural uplift. New launches typically enter semi-regulated markets at lower realizations, then migrate to regulated markets over 2–3 years. This blended effect caps upside but supports durability.

DSM contract (a large pharma company’s in-house supply deal) reached ₹30–35 cr in FY26 and is expected to peak at ~₹60 cr in FY27. This is a visible, material tailwind.

5 — Valuation Discussion: Fair Value Range (Educational Only)

What follows is a walkthrough of how three valuation methods work, using this company’s numbers as the example — not a target, not a forecast, not advice.

Method 1 (P/E Multiple): Annualised EPS is ₹25.98. The peer set (Sun Pharma, Divi’s, Torrent, Cipla, Zydus, Dr Reddy’s, Lupin) trades at a median P/E of 31.34x. The band for Supriya’s peers spans 20.17x (Zydus) to 68.14x (Torrent). Applying the peer median 31.34x to Supriya’s ₹25.98 EPS produces ₹814. Applying the peer range (20–68x) produces ₹520–₹1,766.

Method 2 (EV/EBITDA): Trailing EBITDA is ₹294 cr. Enterprise value is ₹7,321 cr (market